Northwestern Mutual Wealth Management Co. Raises Stake in Zoetis Inc. (NYSE:ZTS)

Northwestern Mutual Wealth Management Co. increased its holdings in Zoetis Inc. (NYSE:ZTS) by 26.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 278,016 shares of the company’s stock after buying an additional 57,902 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Zoetis were worth $48,201,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Aveo Capital Partners LLC purchased a new stake in shares of Zoetis in the 4th quarter worth about $225,000. Gryphon Financial Partners LLC raised its stake in Zoetis by 11.8% in the 4th quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock valued at $601,000 after purchasing an additional 322 shares during the last quarter. Evoke Wealth LLC raised its stake in Zoetis by 14.1% in the 4th quarter. Evoke Wealth LLC now owns 1,675 shares of the company’s stock valued at $331,000 after purchasing an additional 207 shares during the last quarter. California State Teachers Retirement System raised its stake in Zoetis by 0.7% in the 4th quarter. California State Teachers Retirement System now owns 740,935 shares of the company’s stock valued at $146,238,000 after purchasing an additional 5,031 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its stake in Zoetis by 8.7% in the 4th quarter. Jones Financial Companies Lllp now owns 25,213 shares of the company’s stock valued at $4,976,000 after purchasing an additional 2,024 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZTS has been the subject of several analyst reports. Stifel Nicolaus boosted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. Piper Sandler boosted their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. BTIG Research boosted their target price on shares of Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $220.38.

Zoetis Stock Performance

Zoetis stock opened at $194.81 on Monday. The stock has a market cap of $88.26 billion, a P/E ratio of 37.54, a price-to-earnings-growth ratio of 2.99 and a beta of 0.88. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a 50 day moving average of $186.04 and a 200-day moving average of $174.78. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm had revenue of $2.36 billion for the quarter, compared to analysts’ expectations of $2.31 billion. During the same period last year, the business posted $1.41 earnings per share. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. On average, analysts expect that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.